Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Innovent Biologics's Enterprise Value for the quarter that ended in Dec. 2025 was €12,702 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €111 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics EV-to-EBIT Related Terms
Innovent Biologics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Innovent Biologics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's EV-to-EBIT falls into.
Innovent Biologics's current Enterprise Value is €17,553 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €111 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a EV-to-EBIT of 158.29 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovent Biologics and its competitors. According to the industry distribution chart, Innovent Biologics ranks #353 out of 365 companies in the Biotechnology industry, placing it in the top 96.7%.
Is Innovent Biologics' EV-to-EBIT too high?
Innovent Biologics' current EV-to-EBIT is 158.29. The Biotechnology industry median EV-to-EBIT is 15.79. Innovent Biologics' value of 158.29 is 902.5% above this industry median. Based on the distribution chart, Innovent Biologics ranks #353 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #353 out of 365 companies for EV-to-EBIT. This places Innovent Biologics in the lower half of its industry. The industry median EV-to-EBIT is 15.79. Innovent Biologics' value of 158.29 is 902.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.79, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current EV-to-EBIT of 158.29 is 902.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current EV-to-EBIT is 158.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Fairly Valued. The stock's GF Value™ is €11.93, compared to a current price of €11.13 — trading 6.7% below its estimated fair value. The current EV-to-EBIT is 158.29 and 902.5% above the Biotechnology industry median of 15.79. Innovent Biologics' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current EV-to-EBIT is 158.29 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €11.13 is trading 6.7% below its estimated GF Value™ of €11.93.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for STU:6IB:
EV-to-EBIT: 158.29
GF Value™: €11.93 vs. price of €11.13 (6.7% below fair value)
Industry Position: 902.5% above the Biotechnology median (#353 of 365)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
